Consensus Enovis Corporation

Stocks

ENOV

US1940145022

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 14:05:49 2026-07-22 EDT			5-day change	1st Jan Change
26.50 ^USD	-2.21%		+3.63%	-0.45%

07-13	Enovis Corporation Launches Ct-Revitl Laser Therapy System for Veterinary Care	CI
07-09	BMO Capital Initiates Enovis at Outperform With $29 Price Target	MT

Evolution of the Average Target: Enovis Corporation

Evolution of the Target Price: Enovis Corporation

Changes in Analyst Recommendations: Enovis Corporation

3c68c77d265bcd347e7ebb6888e90ea8.v-tWSea5wXZ-CCI_9RUtjKMZ3XN_YbJttHax1gc1v-w.5Y4bM6PSqUE1RWcHp3QAodF0vhQtK9UG40DDl1dPi47MnCB-3uv3BQxPcw~d1dc09d9ea27d89be2d4ea489ef3990d

Analysts' recommendations: Enovis Corporation

07-09	BMO Capital Initiates Enovis at Outperform With $29 Price Target	MT
02-27	Needham Raises Price Target on Enovis to $52 From $49, Keeps Buy Rating	MT
01-06	BTIG Initiates Enovis at Buy With $41 Price Target	MT
25-08-08	Needham Cuts Price Target on Enovis to $49 From $57, Keeps Buy Rating	MT
25-08-08	UBS Adjusts Enovis Price Target to $57 From $65, Maintains Buy Rating	MT
25-05-12	UBS Adjusts Price Target on Enovis to $65 From $75, Maintains Buy Rating	MT
24-10-03	JMP Securities Initiates Enovis at Outperform With $62 Price Target	MT
24-08-08	Needham Adjusts Price Target on Enovis to $65 From $82, Maintains Buy Rating	MT
24-06-13	JPMorgan Initiates Enovis at Neutral With $53 Price Target	MT
24-02-23	Canaccord Genuity Ups Price Target on Enovis to $75 From $73, Maintains Buy Rating	MT
24-02-23	Needham Raises Price Target on Enovis to $82 From $73, Maintains Buy Rating	MT
24-02-13	Stephens Initiates Enovis With Overweight Rating, $72 Price Target	MT
24-01-22	UBS Initiates Coverage on Enovis With Buy Rating, $75 Price Target	MT
24-01-03	William Blair Initiates Enovis at Outperform Rating	MT
23-12-20	Canaccord Genuity Adjusts Enovis Price Target to $71 From $65, Maintains Buy Rating	MT
23-12-15	Needham Adjusts Price Target on Enovis to $70 From $62, Keeps Buy Rating	MT
23-08-04	Baird Adjusts Price Target on Enovis to $70 From $67, Maintains Outperform Rating	MT
23-06-26	Needham Initiates Enovis With Buy Rating, $70 Price Target	MT
23-05-12	Wells Fargo Upgrades Enovis to Overweight Rating From Equal Weight, Adjusts Price Target to $67 From $55	MT
23-02-24	Baird Adjusts Enovis Price Target to $64 From $68, Maintains Outperform Rating	MT
22-11-03	Baird Adjusts Enovis' Price Target to $68 From $73, Keeps Outperform Rating	MT
22-10-26	Wells Fargo Lowers Enovis' Price Target to $53 From $60, Keeps Equalweight Rating	MT
22-10-12	Jefferies Initiates Enovis at Buy with $60 Price Target	MT
22-10-11	Goldman Sachs Initiates Coverage on Enovis With Buy Rating, $57 Price Target	MT
22-09-12	Evercore ISI Starts Enovis at Outperform With $68 Price Target	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
ENOVIS CORPORATION			+50.29%
STRYKER CORPORATION			+22.87%
SMITH & NEPHEW PLC			+21.61%
GLAUKOS CORPORATION			+7.78%
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.			+47.19%
DOUBLE MEDICAL TECHNOLOGY INC.	-	-	+17.3%
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.			+37.58%
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-	-	-
INSPIRE MEDICAL SYSTEMS, INC.			-0.2%
Average			+25.55%
Weighted average by Cap.			+22.70%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.10USD

Average target price

40.73USD

Spread / Average Target

+50.29%

High Price Target

55.00USD

Spread / Highest target

+102.95%

Low Price Target

29.00USD

Spread / Lowest Target

+7.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
Needham & Co.
BTIG
UBS
JMP Securities
JPMorgan Chase
Canaccord Genuity
Stephens Inc.
William Blair & Co.
Baird
Wells Fargo Securities
Jefferies & Co.
Goldman Sachs
Evercore ISI
Argus
Loop Capital
Morgan Stanley
KeyBanc Capital Markets
Stifel Nicolaus
Seaport Global Securities
Deutsche Bank Securities
Barclays